|
South Africa Pharmaceuticals & Healthcare Report |
Was: $1030.00 | |
| Now: $875.00 | ||
| You save: $155.00 (15%) |
The South Africa Pharmaceuticals and Healthcare Report
Independent 5-year pharmaceutical and healthcare industry forecasts for South Africa.
Original pharmaceutical and healthcare market research and pharmaceutical and healthcare sector trend analysis for the South African pharmaceutical and healthcare industry.
Competitive intelligence, South African pharmaceutical and healthcare company rankings and SWOT analyses on international and domestic pharmaceutical and healthcare companies in the South African market.
The South Africa Pharmaceuticals and Healthcare Report has been researched at source and features the latest available data and forecasts to end- covering drugs and healthcare expenditure, the prescription, OTC and generics markets, and foreign trade; company rankings and competitive landscapes including multinational and national drugs companies; and analysis of latest industry news, trends and regulatory developments.
Business Monitor International’s South Africa Pharmaceuticals and Healthcare Report provides industry professionals, market investors and corporate and financial services analysts with independent forecasts and competitive intelligence on the South African pharmaceutical and healthcare industry.
Key Benefits of Report
- Benchmark BMI’s Independent 5-year Pharmaceutical and Healthcare Industry Forecasts on South Africa to test other views – a key input for successful budgeting and strategic business planning in the South African pharmaceutical and healthcare market.
- Target Business Opportunities & Risks in the South African Pharmaceutical and Healthcare Sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in South Africa.
- Exploit The Latest Competitive South African Pharmaceutical and Healthcare Intelligence & company SWOTS on your competitors and peers through company rankings by sales, market share and ownership structure – includes multi-national and national companies in South Africa.
Coverage
Executive Summary & Industry SWOT
An at-a-glance perspective on latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The SWOT outlines strategic factors which affect BMI’s forecast analysis, and taken together with BMI’s Economic and Business Environment SWOTS, give a complete overview of market climate.
Market Summary
Outline of market characteristics, growth factors, leading therapeutic segments and a competitivness of the market.
Regulatory Regime
Guide to and analysis of country intellectual property developments and pricing & reimbursement issues, which constitute the regulatory make-up of the market.
Industry Developments
Focus on government healthcare reforms, epidemiological trends, company M&As, product launches, market entries, FDI activity, R&D and patent legislation.
BMI 5-Year Industry Forecast
5-Year Forecasts to end- for all key industry indicators (see list below), supported by explicit assumptions, plus analysis of key downside risks to the main forecast, including:
- Drug market expenditure (US$bn); drug expenditure per capita (US$); as % of gdp
- Prescription drug market (US$bn)/as % of total market; sales by alimentary tract/metabolism; antibiotics, cardiovascular, central nervous system, oncology, musculoskeletal and respiratory system
- OTC market (US$bn)/as % of total market (sales by analgesic, cough and cold, digestives, skin treatments, vitamins and minerals)
- Generics market (US$bn)/ as % of total market
- Health expenditure (US$bn, % of gdp and per capita); public sector health expenditure as % of total; number of hospitals; beds, hospital admissions, doctors, births and deaths per 000 population
Forecasts based on bespoke BMI economic modelling, using historical data sets of macroeconomic and industry variables to derive rigorous statistical relationships, anchored in advanced linear regression techniques.
BMI 5-Year Macroeconomic Forecasts
BMI forecasts for all headline macroeconomic indicators, including:
Nominal and real GDP, % real GDP growth, % private consumption growth, % industrial output growth, % consumer price index, % GDP price deflator, exports, imports, trade balance, current account balance, foreign direct investment, exchange rate against US$, government expenditure, external debt
Competitive Landscape & Profiles
Intelligence on the market position of major MNC power houses and indigenous companies. BMI profiles key research-based companies. Company SWOTS are provided for all key strategic players, complete with a company activity overview, its leading products and analysis of business opportunities.
|
South Africa Pharmaceuticals & Healthcare Report |
Was: $1030.00 | |
| Now: $875.00 | ||
| You save: $155.00 (15%) |
Chapter - Executive Summary |
| SWOT Analysis |
| South Africa Political SWOT |
| South Africa Economic SWOT |
| South Africa Business Environment SWOT |
| South Africa Pharmaceuticals And Healthcare Industry SWOT |
Chapter - Pharmaceutical Business Environment Ratings |
| Table: Middle East And Africa Pharmaceutical Business Environment Ratings for Q209 |
| Limits to Potential Returns |
| Risks to Realisation of Returns |
Chapter - South Africa – Market Summary |
| Regulatory Regime |
| Table: South Africa Drug Classification System (Section 22A Of Medicines And Related Substance Act 101 Of 1965) |
| Recent Regulatory Developments |
| Table: Proposed Scope Of The South African Health Products Regulatory Authority |
| Pharmaceutical Advertising |
| Intellectual Property Environment |
| Counterfeit Activity |
| Pricing System |
| Recent Pricing Developments |
| Hospital Tenders |
| Table: Companies Involved In South Africa's February 2008 Price Fixing Scandal |
| Reimbursement System |
| Recent Reimbursement Developments |
| Prescription Fees |
Chapter - Industry Developments |
| Epidemiology |
| Table: Leading Causes Of Disease In Africa, 2002 |
| HIV/AIDS |
| Tuberculosis |
| Healthcare Sector |
| Recent Healthcare Sector Developments |
| Private Healthcare Regulation |
| Health Insurance |
| Government Health Insurance |
| Recent Insurance Industry Developments |
| Domestic Pharmaceutical Sector |
| Table: PIASA Membership |
| Domestic Company Developments |
| ARV Manufacturing and Government Tenders |
| Foreign Pharmaceutical Sector |
| Foreign Company Developments |
| Retail Pharmacy Sector |
| Research and Development Sector |
| Recent R&D Activities |
| Vaccines |
| Traditional African Medicine |
| Medical Devices |
| Table: South African Customs Classification Of Medical Devices |
| Regional Developments in Medical Devices Sector |
| Table: Aims Of PEPFAR-BD Partnership |
Chapter - Industry Forecast Scenario |
| Overall Market Forecast |
| Table: South Africa - Drug Expenditure Indicators, Historical Data and Forecasts |
| Key Growth Factors – Industry |
| Table: South Africa - Health Expenditure Indicators, Historical Data and Forecasts |
| Key Growth Factors – Macroeconomic Chapter - |
| Table: South Africa - Economic Activity |
| Prescription Market Forecast |
| Table: South Africa - Prescription Market Indicators, Historical Data and Forecasts (ZARmn unless otherwise stated) |
| Patented Market Forecast |
| Table: South Africa - Patented Drug Market Forecast Indicators, Historical Data and Forecasts |
| Generics Market Forecast |
| Table: South Africa - Generic Market Indicators, Historical Data and Forecasts |
| OTC Market Forecast |
| Table: South Africa – OTC Drug Market Indicators, Historical Data and Forecasts (US$mn unless otherwise stated) |
| Medical Device Forecast |
| Table: South Africa – Medical Device Market, Historical Data and Forecasts (US$mn unless otherwise stated) |
| Pharmaceutical Trade Forecasts |
| Table: South Africa – Export And Import Trade Indicators, Historical Data and Forecasts (US$mn) |
| Other Healthcare Data |
| Table: South Africa – Other Healthcare Indicators, Historical Data and Forecasts |
| Key Risks to BMI's Forecast Scenario |
Chapter - Competitive Landscape |
| Table: Private Market Size for Selected Products in South Africa* (2007) |
| Table: Top 10 Drugmakers In South Africa, 2006 |
Chapter - Company Monitor |
| Leading Foreign Companies |
| Sanofi-Aventis |
| Pfizer |
| Roche |
| GlaxoSmithKline |
| Merck & Co |
| Leading Indigenous Manufacturers |
| Aspen Pharmacare |
| Adcock Ingram |
| Enaleni Pharmaceuticals (Cipla-Medpro) |
Chapter - Country Snapshot: South Africa Demographic Data |
| Section 1: Population |
| Table: Demographic Indicators, 2005-2030 |
| Table: Rural/Urban Breakdown, 2005-2030 |
| Section 2: Education and Healthcare |
| Table: Education, 2002-2005 |
| Table: Vital Statistics, 2005-2030 |
| Section 3: Labour Market and Spending Power |
| Table: Employment Indicators, 2001-2006 |
| Table: Consumer Expenditure, 2000-2012 (US$) |
| Table: Average Annual Wages, 2000-2012 |
Chapter - BMI Forecast Modelling |
| How We Generate Our Pharmaceutical Industry Forecasts |
| Pharmaceutical Business Environment Ratings Methodology |
| Ratings Overview |
| Table: Pharmaceutical Business Environment Indicators |
| Weighting |
| Table: Weighting Of Components |
| Sources |
|
South Africa Pharmaceuticals & Healthcare Report |
Was: $1030.00 | |
| Now: $875.00 | ||
| You save: $155.00 (15%) |
In BMI’s Business Environment Ratings for Q209, South Africa’s position continued to worsen, with the country slipping from sixth to seventh position of the 17 Middle East and Africa (MEA) markets surveyed. Key reasons behind this slide include the strict pricing and reimbursement regime, as well as the uncertainty regarding the financial viability of the public healthcare system, given the massive number of HIV/AIDS sufferers, who are supposed to be receiving free treatment. Nevertheless, South Africa will remain one of the key pharmaceutical markets in the region, posting a compound annual growth rate (CAGR) of 8.97% in local currency terms through to 2013. By that time, BMI expects that the market will be worth around US$3.9bn, up on the estimated 2008 figure of US$2.5bn. The recent formation of a new, streamlined regulatory body should support the faster processing of drug applications, although generics are expected to continue gaining a market share at the expense of patented products.
However, the forecasts are at risk of a fluctuating exchange rate. During Q408, the rand depreciated by 18.6% to ZAR9.53/US$, with a lower value against the euro at ZAR13.28/EUR, a decrease of 14.8% since September 2008. BMI’s Country Risk team forecasts that local tender will further depreciate in the course of 2009, not returning to pre-2008 levels before 2013. In January 2009, to address the impact of this trend and prevent medicines shortages, the South African government authorised up to 13.2% price increases for the country's generic pharmaceutical firms. BMI believes that the agreed rise in generic pharmaceutical charges will be a temporary measure until the exchange rate against the dollar improves, when the government is likely to go ahead with the planned 40% pricing benchmark for generic medicines against their patented counterparts.
Around the same time, South African doctors began a discussion with the Department of Health (DoH) to address the ongoing issues concerning prescription fee charges, which are capped at 16% on all prescription drugs costing above US$10. Doctors consider the fee too low, given that it is meant to cover storing expenses, which are considerable in remote areas. While the demanded 30-40% cap is unlikely to be achieved, the government will probably seek to meet part of the doctors’ request, judging by previous cases pertaining to dispensing fees.
In the meantime, while it is not currently our core scenario that South Africa will slip into a full-blown recession over the course of 2009, the country's open, export-oriented economy and financial markets could be more heavily exposed to the downturn in external conditions than anticipated, especially given the current political uncertainty. While leading indicators suggest that private consumption remains under immense pressure, the deceleration in inflationary pressures and expectations of further decreases have given a (short-term) boost to consumer sentiment, which should have a positive development on medical consumption, as drugs remain regarded as some of the most essential items.
|
South Africa Pharmaceuticals & Healthcare Report |
Was: $1030.00 | |
| Now: $875.00 | ||
| You save: $155.00 (15%) |
Africa |
| Algeria, Egypt, Kenya, Morocco, Nigeria and Zimbabwe |
Asia |
| Australia, Bangladesh, China, Hong Kong, India, Indonesia, Japan, Malaysia, Pakistan, Philippines, Singapore, South Korea, Taiwan, Thailand and Vietnam |
Caribbean |
| Puerto Rico |
Europe |
| Belarus, Belgium, Bulgaria, Croatia, Czech Republic, Estonia, France, Germany, Greece, Hungary, Italy, Kazakhstan, Latvia, Lithuania, Moldova, Netherlands, Poland, Portugal, Romania, Russia, Serbia, Slovakia, Slovenia, Spain, Switzerland, Ukraine, United Kingdom and Uzbekistan |
Latin America |
| Argentina, Brazil, Chile, Colombia, Mexico, Peru and Venezuela |
Middle East |
| Bahrain, Iran, Israel, Jordan, Kuwait, Lebanon, Oman, Qatar, Saudi Arabia, Turkey and United Arab Emirates |
North America |
| Canada and United States |
Business Monitor InternationalA Market Leader in Country Risk, Industry Intelligence and Company Research Mermaid House, 2 Puddle Dock, Blackfriars, London EC4V 3DS, UK |
BUSINESS MONITOR INTERNATIONAL's country risk analysis and forecasts, market research on leading industries, and multinational company research is relied upon by corporates, banks, government departments and multilateral organisations in over 125 countries around the world. Country Risk Analysis and Forecasts Industry Intelligence and Market Research Company Research |